INTRODUCTION
============

Recent studies have shown that the angiotensin receptor blocker (ARB) olmesartan medoxomil induces a sprue-like illness characterized by diarrhea and malabsorption.[@B1][@B2][@B3] This disease affects men and women equally, and most cases have been reported in men and women aged 60 to 80 years. The common presentation of this disease is chronic diarrhea with weight loss, and some patients present with fatigue, nausea, vomiting, abdominal pain, and bloating. Majority of the patients exhibit total or partial villous atrophy, which improves with drug withdrawal.[@B1] Several studies have reported sprue-like enteropathy associated with olmesartan; however, only 5 cases of patients with sprue-like enteropathy associated with telmisartan, valsartan, irbesartan, and eprosartan have been reported thus far.[@B1][@B4][@B5][@B6][@B7][@B8] The patient with telmisartan-induced sprue-like enteropathy exhibited ileitis with colitis without the involvement of the duodenum.[@B4] To our knowledge, our study has reported telmisartan-induced sprue-like enteropathy involving the duodenum for the first time.

CASE REPORT
===========

A 45-year-old woman with hypothyroidism and hypertension and a history of chronic kidney disease had presented with chronic diarrhea and weight loss of 10 kg for the past 8 months. She had anemia, and her hemoglobin level was 10.3 g/dL; total leukocyte count was 7,600×10^3^/dL; and platelet count was 2.34×10^3^/dL. She also exhibited impaired renal function with BUN and creatinine levels of 67 mg/dL and 2.1 mg/dL, respectively. She had hypoalbuminemia with an albumin level of 2.7 g/dL. The results of the liver function test were normal, and her total bilirubin level was 0.9 mg/dL; direct bilirubin level was 0.2 mg/dL; aspartate transaminase level was 26 IU/L; alanine transaminase level was 20 IU/L; and ALP level was 117 IU/L. Electrocardiograph showed left ventricular hypertrophy, and the chest radiograph showed no abnormalities. To determine the cause of diarrhea, we performed the routine stool examination and culture, which were noncontributory. Further, the results of serological examination for celiac disease (IgA anti-tissue transglutaminase antibody) were negative. Her upper gastrointestinal endoscopy revealed typical scalloping and grooving with nodularity ([Fig. 1](#F1){ref-type="fig"}). Multiple samples were taken from the second part of the duodenum and biopsy was performed, which showed subtotal atrophy of the duodenal villous pattern ([Fig. 2](#F2){ref-type="fig"}). The patient had been prescribed telmisartan 40 mg daily for hypertension for the past 1 year. After discontinuation of telmisartan and switching to amlodipine, diarrhea subsided, renal function improved, and significant weight gain was observed. Follow-up endoscopy showed normal duodenal folds 4 months after discontinuation of telmisartan.

DISCUSSION
==========

Several recent studies have reported olmesartan-induced sprue-like enteropathy.[@B1][@B2][@B3][@B4] A systematic review of 54 cases of olmesartan-induced sprue-like enteropathy showed that 64% patients were human leukocyte antigen (HLA) DQ2/DQ8 positive, whereas the incidence of HLA DQ2/DQ8-positive individuals is 40% among the general population; therefore, the involvement of the HLA system in this disease cannot be ruled out.[@B3] Interestingly, similar to patients with celiac sprue, some patients with sprue-like enteropathy show a subepithelial collagen band, with one-third having lymphocytic gastritis.[@B2][@B3]

The pathogenesis underlying this condition is unclear; however, it is believed that angiotensin II plays a proapoptotic role by acting on angiotensin (AT) 2 receptors in the proximal gut because of selective saturation of AT 1 receptors by sartans; further, impaired interleukin-15 signaling and disruption of the tight junction protein zonula occludens-1 has been implicated in this condition.[@B9][@B10]

A recent study reported the case of a patient with telmisartan-induced collagenous ileitis, colitis, and gastritis; however, this patient showed normal pattern of the duodenal villi on endoscopy of the upper gastrointestinal tract, and biopsy of the duodenum showed no abnormalities.[@B4] A previous study has shown sprue-like enteropathy associated with irbesartan and valsartan.[@B1]

To our knowledge, this is the first study to report on the association between telmisartan and sprue-like enteropathy involving the duodenum. The cases of patients with spruelike enteropathy caused by ARBs belonging to the sartan class other than olmesartan are shown in [Table 1](#T1){ref-type="table"}.[@B4][@B5][@B6][@B7][@B8] Our results indicate that sprue-like enteropathy is associated with the sartan class of ARBs rather than a single drug. Therefore, the possibility of sprue-like enteropathy should be considered as a differential diagnosis in patients who receive antihypertensives belonging to the sartan class, develop new-onset diarrhea, undergo weight loss, or show features of malabsorption.
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###### Report of Non-olmesartan Angiotensin Receptor Blocker-Related Cases of Sprue-Like Enteropathy
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  Case           Age (yr)   Sex      Causing drug   Duration of drug use   Involved organ              Pathologic findings                                                                                                                   Clinical outcome
  -------------- ---------- -------- -------------- ---------------------- --------------------------- ------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------
  Case 1[@B4]    71         Female   Telmisartan    2 mo                   Colon, ileum, and stomach   Severe villous atrophy, intraepithelial lymphocytosis, subepithelial collagen band in terminal ileum, colonic, and stomach biopsies   Symptoms and histology improved in 7 mo of stopping the drug
  Case 2[@B7]    80         Female   Irbesartan     6 mo                   Duodenum                    Total atrophy of villous pattern                                                                                                      Improved clinically and histologically within 3 mo
  Case 3[@B8]    54         Female   Irbesartan     9 mo                   Duodenum                    Total villous atrophy                                                                                                                 Clinical improvement after stopping the drug
  Case 4[@B9]    71         Female   Valsartan      5 yr                   Duodenum and jejunum        Complete villous atrophy, intraepithelial lymphocytosis, and crypt hyperplasia                                                        Improved after stopping the drug
  Case 5[@B10]   83         Female   Eprosartan     10 yr                  Duodenum                    Flattened mucosa and increase in ntraepithelial lymphocytesand                                                                        Improved
  Present case   45         Female   Telmisartan    1 yr                   Duodenum                    Subtotal atrophy of the duodenal villous pattern                                                                                      Clinical and histological improvement
